South Korea · Delayed Price · Currency is KRW EyeGene Statistics
Total Valuation
EyeGene has a market cap or net worth of KRW 63.98 billion. The enterprise value is 21.85 billion.
| Market Cap | 63.98B |
| Enterprise Value | 21.85B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EyeGene has 43.23 million shares outstanding. The number of shares has increased by 18.73% in one year.
| Current Share Class | 43.23M |
| Shares Outstanding | 43.23M |
| Shares Change (YoY) | +18.73% |
| Shares Change (QoQ) | +40.61% |
| Owned by Insiders (%) | 6.13% |
| Owned by Institutions (%) | n/a |
| Float | 30.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.91 |
| PB Ratio | 1.21 |
| P/TBV Ratio | 1.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.35 |
| EV / Sales | 5.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.55 |
Financial Position
The company has a current ratio of 5.46, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.46 |
| Quick Ratio | 5.32 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.06 |
| Interest Coverage | -17.45 |
Financial Efficiency
Return on equity (ROE) is -38.34% and return on invested capital (ROIC) is -12.99%.
| Return on Equity (ROE) | -38.34% |
| Return on Assets (ROA) | -10.73% |
| Return on Invested Capital (ROIC) | -12.99% |
| Return on Capital Employed (ROCE) | -19.37% |
| Weighted Average Cost of Capital (WACC) | 9.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.06 |
| Inventory Turnover | 4.38 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.97% in the last 52 weeks. The beta is 0.74, so EyeGene's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | -53.97% |
| 50-Day Moving Average | 1,547.04 |
| 200-Day Moving Average | 1,884.61 |
| Relative Strength Index (RSI) | 42.77 |
| Average Volume (20 Days) | 3,921,234 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EyeGene had revenue of KRW 4.02 billion and -16.22 billion in losses. Loss per share was -506.72.
| Revenue | 4.02B |
| Gross Profit | 1.17B |
| Operating Income | -10.97B |
| Pretax Income | -19.65B |
| Net Income | -16.22B |
| EBITDA | -8.96B |
| EBIT | -10.97B |
| Loss Per Share | -506.72 |
Balance Sheet
The company has 41.69 billion in cash and 524.25 million in debt, with a net cash position of 41.16 billion or 952.22 per share.
| Cash & Cash Equivalents | 41.69B |
| Total Debt | 524.25M |
| Net Cash | 41.16B |
| Net Cash Per Share | 952.22 |
| Equity (Book Value) | 52.92B |
| Book Value Per Share | 1,249.07 |
| Working Capital | 35.94B |
Cash Flow
In the last 12 months, operating cash flow was -8.47 billion and capital expenditures -104.85 million, giving a free cash flow of -8.57 billion.
| Operating Cash Flow | -8.47B |
| Capital Expenditures | -104.85M |
| Depreciation & Amortization | 2.01B |
| Net Borrowing | -2.15B |
| Free Cash Flow | -8.57B |
| FCF Per Share | -198.25 |
Margins
| Gross Margin | 28.98% |
| Operating Margin | -272.82% |
| Pretax Margin | -488.57% |
| Profit Margin | n/a |
| EBITDA Margin | -222.82% |
| EBIT Margin | -272.82% |
| FCF Margin | n/a |
Dividends & Yields
EyeGene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.73% |
| Shareholder Yield | -18.73% |
| Earnings Yield | -25.35% |
| FCF Yield | -13.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 28, 2021. It was a forward split with a ratio of 1.2.
| Last Split Date | Jun 28, 2021 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
EyeGene has an Altman Z-Score of -0.06 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.06 |
| Piotroski F-Score | 3 |